Mitchell Mcgill
Concepts (332)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 66 | 2025 | 276 | 13.280 |
Why?
| Liver | 50 | 2025 | 1132 | 5.520 |
Why?
| Analgesics, Non-Narcotic | 19 | 2025 | 117 | 4.060 |
Why?
| Drug Overdose | 19 | 2025 | 159 | 2.960 |
Why?
| Hepatocytes | 24 | 2024 | 178 | 2.390 |
Why?
| Liver Failure, Acute | 7 | 2025 | 56 | 1.940 |
Why?
| Oxidative Stress | 16 | 2024 | 772 | 1.850 |
Why?
| Animals | 70 | 2025 | 13124 | 1.840 |
Why?
| Mice, Inbred C57BL | 38 | 2025 | 1808 | 1.770 |
Why?
| Alanine Transaminase | 13 | 2025 | 119 | 1.740 |
Why?
| Liver Regeneration | 5 | 2019 | 47 | 1.610 |
Why?
| Glutathione | 15 | 2025 | 299 | 1.590 |
Why?
| Mice | 42 | 2025 | 5687 | 1.360 |
Why?
| Mitochondria, Liver | 8 | 2016 | 69 | 1.320 |
Why?
| Mitochondria | 9 | 2020 | 399 | 1.200 |
Why?
| Cochlea | 2 | 2019 | 17 | 1.170 |
Why?
| JNK Mitogen-Activated Protein Kinases | 12 | 2015 | 71 | 1.140 |
Why?
| Glutamate Dehydrogenase | 6 | 2025 | 16 | 1.130 |
Why?
| End Stage Liver Disease | 2 | 2023 | 47 | 0.990 |
Why?
| Imines | 1 | 2025 | 14 | 0.990 |
Why?
| Benzoquinones | 1 | 2025 | 32 | 0.980 |
Why?
| DNA, Mitochondrial | 6 | 2017 | 111 | 0.970 |
Why?
| Methamphetamine | 3 | 2022 | 194 | 0.950 |
Why?
| DNA Fragmentation | 5 | 2016 | 53 | 0.930 |
Why?
| Protective Agents | 2 | 2024 | 16 | 0.930 |
Why?
| Liver Diseases | 3 | 2025 | 80 | 0.920 |
Why?
| Plant Extracts | 7 | 2024 | 174 | 0.910 |
Why?
| Dietary Supplements | 3 | 2024 | 449 | 0.870 |
Why?
| Humans | 57 | 2025 | 50503 | 0.810 |
Why?
| Male | 49 | 2025 | 25907 | 0.810 |
Why?
| Acetylcysteine | 4 | 2024 | 101 | 0.780 |
Why?
| Phosphatidic Acids | 2 | 2019 | 6 | 0.760 |
Why?
| Necrosis | 12 | 2020 | 174 | 0.730 |
Why?
| Antioxidants | 4 | 2023 | 239 | 0.720 |
Why?
| Cannabidiol | 4 | 2024 | 40 | 0.690 |
Why?
| Disease Models, Animal | 8 | 2019 | 1436 | 0.680 |
Why?
| Xenobiotics | 2 | 2019 | 28 | 0.660 |
Why?
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 4 | 0.640 |
Why?
| ortho-Aminobenzoates | 1 | 2019 | 6 | 0.640 |
Why?
| Apoptosis | 9 | 2016 | 1097 | 0.630 |
Why?
| Liver Cirrhosis | 1 | 2021 | 229 | 0.630 |
Why?
| Pharmaceutical Preparations | 1 | 2019 | 76 | 0.610 |
Why?
| Stilbenes | 2 | 2015 | 52 | 0.610 |
Why?
| Phosphatidate Phosphatase | 1 | 2018 | 14 | 0.590 |
Why?
| Cytochrome P-450 Enzyme System | 6 | 2020 | 194 | 0.590 |
Why?
| Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2014 | 5 | 0.590 |
Why?
| Sulfonamides | 1 | 2019 | 126 | 0.580 |
Why?
| Drug Delivery Systems | 1 | 2019 | 143 | 0.570 |
Why?
| Enzyme Inhibitors | 2 | 2019 | 377 | 0.560 |
Why?
| Reactive Oxygen Species | 5 | 2015 | 409 | 0.560 |
Why?
| Pyridines | 2 | 2015 | 131 | 0.550 |
Why?
| Brain | 1 | 2025 | 1319 | 0.550 |
Why?
| C-Reactive Protein | 1 | 2018 | 144 | 0.550 |
Why?
| Paraproteins | 1 | 2016 | 13 | 0.540 |
Why?
| Nuclear Proteins | 1 | 2018 | 238 | 0.530 |
Why?
| Electron Transport Chain Complex Proteins | 2 | 2017 | 9 | 0.530 |
Why?
| Immunoglobulin M | 1 | 2016 | 58 | 0.520 |
Why?
| Creatinine | 1 | 2016 | 145 | 0.520 |
Why?
| Ethylmaleimide | 1 | 2015 | 3 | 0.510 |
Why?
| Sulfhydryl Reagents | 1 | 2015 | 3 | 0.510 |
Why?
| Glutathione Reductase | 1 | 2015 | 14 | 0.510 |
Why?
| Hearing | 1 | 2016 | 61 | 0.500 |
Why?
| Signal Transduction | 6 | 2022 | 1624 | 0.500 |
Why?
| DNA | 3 | 2022 | 535 | 0.480 |
Why?
| Furosemide | 1 | 2014 | 11 | 0.480 |
Why?
| Antidotes | 2 | 2014 | 27 | 0.460 |
Why?
| Argininosuccinate Synthase | 1 | 2014 | 1 | 0.460 |
Why?
| Dose-Response Relationship, Drug | 12 | 2024 | 1372 | 0.450 |
Why?
| Protein Binding | 8 | 2018 | 654 | 0.440 |
Why?
| Carnitine | 1 | 2013 | 63 | 0.420 |
Why?
| Diosgenin | 1 | 2012 | 1 | 0.410 |
Why?
| Female | 22 | 2025 | 27081 | 0.400 |
Why?
| Cannabis | 4 | 2024 | 146 | 0.390 |
Why?
| Rats, Wistar | 3 | 2022 | 224 | 0.390 |
Why?
| Rats | 6 | 2025 | 3292 | 0.390 |
Why?
| Prognosis | 5 | 2023 | 1978 | 0.390 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 121 | 0.370 |
Why?
| Critical Illness | 1 | 2013 | 302 | 0.360 |
Why?
| Young Adult | 9 | 2021 | 4102 | 0.350 |
Why?
| Middle Aged | 15 | 2025 | 12611 | 0.350 |
Why?
| Drug Evaluation, Preclinical | 3 | 2024 | 145 | 0.350 |
Why?
| Autophagy | 4 | 2021 | 170 | 0.330 |
Why?
| Cell Death | 6 | 2020 | 175 | 0.320 |
Why?
| Bile Ducts | 2 | 2020 | 49 | 0.320 |
Why?
| Keratin-18 | 3 | 2021 | 14 | 0.320 |
Why?
| Mice, Knockout | 9 | 2025 | 844 | 0.320 |
Why?
| HMGB1 Protein | 3 | 2021 | 21 | 0.320 |
Why?
| Oxidation-Reduction | 2 | 2023 | 316 | 0.310 |
Why?
| Kinetics | 3 | 2025 | 623 | 0.310 |
Why?
| Connexins | 3 | 2016 | 25 | 0.290 |
Why?
| Glutathione Disulfide | 3 | 2016 | 40 | 0.280 |
Why?
| Reperfusion Injury | 2 | 2020 | 86 | 0.270 |
Why?
| Adult | 12 | 2025 | 13577 | 0.260 |
Why?
| Amino Acid Chloromethyl Ketones | 2 | 2016 | 10 | 0.260 |
Why?
| Kupffer Cells | 1 | 2025 | 11 | 0.250 |
Why?
| Hepatitis | 2 | 2016 | 21 | 0.250 |
Why?
| Receptors, Immunologic | 1 | 2025 | 35 | 0.240 |
Why?
| MicroRNAs | 3 | 2020 | 344 | 0.240 |
Why?
| Cholestasis | 2 | 2015 | 40 | 0.240 |
Why?
| Time Factors | 7 | 2019 | 2935 | 0.230 |
Why?
| Ischemia | 2 | 2016 | 153 | 0.230 |
Why?
| Lab-On-A-Chip Devices | 1 | 2024 | 9 | 0.230 |
Why?
| Models, Biological | 3 | 2019 | 716 | 0.230 |
Why?
| Pyruvic Acid | 1 | 2023 | 21 | 0.220 |
Why?
| Mitochondrial Proteins | 2 | 2015 | 88 | 0.220 |
Why?
| Alanine | 1 | 2023 | 43 | 0.220 |
Why?
| Lung | 2 | 2019 | 504 | 0.210 |
Why?
| Antipyretics | 2 | 2013 | 3 | 0.210 |
Why?
| 5-Methylcytosine | 1 | 2022 | 16 | 0.210 |
Why?
| Severity of Illness Index | 2 | 2023 | 978 | 0.210 |
Why?
| DNA Damage | 2 | 2014 | 301 | 0.200 |
Why?
| Cysteine | 2 | 2013 | 50 | 0.200 |
Why?
| Macrophages | 1 | 2025 | 364 | 0.200 |
Why?
| Amphetamine | 1 | 2022 | 38 | 0.190 |
Why?
| Phosphorylation | 3 | 2019 | 525 | 0.190 |
Why?
| Half-Life | 1 | 2022 | 86 | 0.190 |
Why?
| Proliferating Cell Nuclear Antigen | 2 | 2019 | 68 | 0.190 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 238 | 0.190 |
Why?
| Risk Assessment | 2 | 2023 | 1270 | 0.180 |
Why?
| Drug Administration Schedule | 1 | 2021 | 370 | 0.180 |
Why?
| Adenosylhomocysteinase | 1 | 2020 | 9 | 0.170 |
Why?
| Alcohol Dehydrogenase | 1 | 2020 | 37 | 0.170 |
Why?
| Aldehyde Dehydrogenase | 1 | 2020 | 25 | 0.170 |
Why?
| Granzymes | 1 | 2020 | 10 | 0.170 |
Why?
| Enzyme Activation | 3 | 2014 | 268 | 0.160 |
Why?
| Biological Transport, Active | 1 | 2019 | 30 | 0.160 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 9 | 0.160 |
Why?
| Sulfotransferases | 1 | 2019 | 39 | 0.160 |
Why?
| Aged | 5 | 2018 | 9741 | 0.160 |
Why?
| Anti-Obesity Agents | 1 | 2019 | 17 | 0.160 |
Why?
| Tea | 1 | 2019 | 17 | 0.160 |
Why?
| Bronchoconstriction | 1 | 2019 | 6 | 0.160 |
Why?
| Systems Biology | 1 | 2019 | 32 | 0.160 |
Why?
| Haptoglobins | 1 | 2018 | 4 | 0.160 |
Why?
| Pilot Projects | 1 | 2021 | 698 | 0.160 |
Why?
| Anemia, Hemolytic | 1 | 2018 | 10 | 0.160 |
Why?
| Hemolysis | 1 | 2018 | 28 | 0.160 |
Why?
| Cell Communication | 1 | 2019 | 68 | 0.160 |
Why?
| Aged, 80 and over | 2 | 2018 | 3226 | 0.160 |
Why?
| Carbon Tetrachloride | 1 | 2018 | 22 | 0.150 |
Why?
| Liver Transplantation | 1 | 2020 | 154 | 0.150 |
Why?
| Cells, Cultured | 7 | 2016 | 1571 | 0.150 |
Why?
| Myoglobin | 1 | 2018 | 25 | 0.150 |
Why?
| Locomotion | 1 | 2019 | 84 | 0.150 |
Why?
| Acetylglucosamine | 1 | 2018 | 6 | 0.150 |
Why?
| Immune Tolerance | 1 | 2018 | 84 | 0.150 |
Why?
| Glucuronosyltransferase | 1 | 2019 | 122 | 0.150 |
Why?
| beta Catenin | 1 | 2019 | 97 | 0.150 |
Why?
| Anthracenes | 2 | 2014 | 8 | 0.150 |
Why?
| N-Acetylglucosaminyltransferases | 1 | 2018 | 14 | 0.150 |
Why?
| Cell Line | 3 | 2015 | 988 | 0.150 |
Why?
| Pregnancy | 1 | 2025 | 2452 | 0.150 |
Why?
| Central Nervous System Stimulants | 1 | 2020 | 209 | 0.150 |
Why?
| Hep G2 Cells | 3 | 2015 | 36 | 0.150 |
Why?
| Bronchodilator Agents | 1 | 2019 | 76 | 0.150 |
Why?
| Inflammation | 2 | 2020 | 610 | 0.140 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2018 | 78 | 0.140 |
Why?
| Lysosomes | 2 | 2021 | 67 | 0.140 |
Why?
| Dexamethasone | 1 | 2020 | 432 | 0.140 |
Why?
| Bacteria | 1 | 2019 | 218 | 0.140 |
Why?
| Genetic Variation | 1 | 2018 | 207 | 0.140 |
Why?
| Prospective Studies | 2 | 2021 | 2378 | 0.140 |
Why?
| Cell Proliferation | 2 | 2019 | 985 | 0.140 |
Why?
| Obesity | 2 | 2018 | 1121 | 0.140 |
Why?
| Caspase Inhibitors | 1 | 2016 | 16 | 0.140 |
Why?
| Gene Expression | 1 | 2019 | 610 | 0.130 |
Why?
| Case-Control Studies | 3 | 2014 | 1156 | 0.130 |
Why?
| False Positive Reactions | 1 | 2016 | 59 | 0.130 |
Why?
| Kidney Function Tests | 1 | 2016 | 51 | 0.130 |
Why?
| Proteomics | 3 | 2022 | 314 | 0.130 |
Why?
| Caspases | 1 | 2016 | 103 | 0.130 |
Why?
| Connexin 43 | 1 | 2016 | 25 | 0.130 |
Why?
| Benzyl Alcohol | 1 | 2015 | 3 | 0.130 |
Why?
| Acetanilides | 1 | 2015 | 1 | 0.130 |
Why?
| Analytic Sample Preparation Methods | 1 | 2015 | 4 | 0.130 |
Why?
| Solid Phase Extraction | 1 | 2015 | 12 | 0.130 |
Why?
| Taurocholic Acid | 1 | 2015 | 5 | 0.130 |
Why?
| Glycochenodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Species Specificity | 2 | 2015 | 187 | 0.130 |
Why?
| Prevalence | 1 | 2019 | 971 | 0.130 |
Why?
| Neutrophils | 2 | 2016 | 145 | 0.130 |
Why?
| Receptors, Proteinase-Activated | 1 | 2015 | 4 | 0.130 |
Why?
| Protein Stability | 1 | 2015 | 43 | 0.130 |
Why?
| Antithrombin III | 1 | 2015 | 12 | 0.120 |
Why?
| Endonucleases | 1 | 2015 | 15 | 0.120 |
Why?
| Caspase 3 | 2 | 2012 | 93 | 0.120 |
Why?
| Nerve Tissue Proteins | 1 | 2016 | 194 | 0.120 |
Why?
| Peptide Hydrolases | 1 | 2015 | 61 | 0.120 |
Why?
| Glycodeoxycholic Acid | 1 | 2014 | 6 | 0.120 |
Why?
| Predictive Value of Tests | 2 | 2014 | 930 | 0.120 |
Why?
| Blood Proteins | 1 | 2015 | 84 | 0.120 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2016 | 393 | 0.120 |
Why?
| Body Mass Index | 1 | 2018 | 677 | 0.120 |
Why?
| Reactive Nitrogen Species | 2 | 2011 | 23 | 0.110 |
Why?
| Up-Regulation | 1 | 2016 | 446 | 0.110 |
Why?
| Gene Expression Regulation | 3 | 2016 | 955 | 0.110 |
Why?
| Aldehyde Oxidase | 1 | 2013 | 1 | 0.110 |
Why?
| Allopurinol | 1 | 2013 | 7 | 0.110 |
Why?
| Neutrophil Activation | 1 | 2014 | 14 | 0.110 |
Why?
| ROC Curve | 1 | 2014 | 226 | 0.110 |
Why?
| Boron Compounds | 1 | 2013 | 19 | 0.110 |
Why?
| Hematopoietic Stem Cells | 1 | 2015 | 197 | 0.110 |
Why?
| Gap Junctions | 1 | 2013 | 26 | 0.110 |
Why?
| Cohort Studies | 1 | 2018 | 1452 | 0.110 |
Why?
| Receptors, Formyl Peptide | 1 | 2013 | 4 | 0.110 |
Why?
| Acute-Phase Reaction | 1 | 2013 | 8 | 0.100 |
Why?
| Sex Characteristics | 1 | 2014 | 198 | 0.100 |
Why?
| Phytotherapy | 1 | 2013 | 45 | 0.100 |
Why?
| Purinergic P2X Receptor Antagonists | 1 | 2012 | 2 | 0.100 |
Why?
| Cathepsin B | 1 | 2012 | 6 | 0.100 |
Why?
| Blood Platelets | 1 | 2015 | 251 | 0.100 |
Why?
| Chemokines | 1 | 2013 | 75 | 0.100 |
Why?
| MAP Kinase Kinase 4 | 1 | 2012 | 29 | 0.100 |
Why?
| Tetrazoles | 1 | 2012 | 41 | 0.100 |
Why?
| Glutathione Transferase | 1 | 2013 | 172 | 0.100 |
Why?
| Metabolomics | 1 | 2013 | 135 | 0.100 |
Why?
| Rats, Inbred F344 | 1 | 2012 | 197 | 0.100 |
Why?
| NF-E2-Related Factor 2 | 1 | 2012 | 40 | 0.100 |
Why?
| Reproducibility of Results | 1 | 2015 | 1197 | 0.100 |
Why?
| Microtubule-Associated Proteins | 1 | 2012 | 66 | 0.100 |
Why?
| Models, Theoretical | 1 | 2013 | 170 | 0.100 |
Why?
| Survival Rate | 1 | 2014 | 909 | 0.100 |
Why?
| Liver Function Tests | 3 | 2019 | 45 | 0.090 |
Why?
| Kidney | 1 | 2015 | 696 | 0.090 |
Why?
| Gentiana | 1 | 2010 | 1 | 0.090 |
Why?
| Ligation | 2 | 2020 | 62 | 0.080 |
Why?
| L-Lactate Dehydrogenase | 2 | 2022 | 60 | 0.080 |
Why?
| Adolescent | 3 | 2016 | 6443 | 0.080 |
Why?
| Chaperonin 60 | 1 | 2008 | 5 | 0.080 |
Why?
| Mice, Inbred Strains | 2 | 2019 | 160 | 0.080 |
Why?
| Computer Simulation | 2 | 2020 | 279 | 0.080 |
Why?
| Rats, Sprague-Dawley | 1 | 2012 | 1585 | 0.080 |
Why?
| Recombinant Fusion Proteins | 1 | 2008 | 179 | 0.070 |
Why?
| Cell Line, Tumor | 1 | 2011 | 1398 | 0.070 |
Why?
| Cytochrome P-450 CYP2E1 | 2 | 2020 | 111 | 0.060 |
Why?
| Primary Cell Culture | 2 | 2015 | 60 | 0.060 |
Why?
| Reference Values | 1 | 2025 | 307 | 0.060 |
Why?
| Peroxynitrous Acid | 2 | 2015 | 33 | 0.050 |
Why?
| Cyclosporine | 2 | 2015 | 66 | 0.050 |
Why?
| Cytokines | 2 | 2016 | 606 | 0.050 |
Why?
| Methylation | 1 | 2022 | 118 | 0.050 |
Why?
| Vitamins | 1 | 2022 | 63 | 0.050 |
Why?
| Sex Factors | 1 | 2025 | 712 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2025 | 859 | 0.050 |
Why?
| Plant Preparations | 1 | 2022 | 39 | 0.050 |
Why?
| Interleukin-10 | 1 | 2022 | 84 | 0.050 |
Why?
| Ligands | 1 | 2022 | 203 | 0.050 |
Why?
| Chromatography, Liquid | 1 | 2022 | 231 | 0.050 |
Why?
| Age Factors | 1 | 2025 | 1110 | 0.050 |
Why?
| Cytoprotection | 2 | 2012 | 34 | 0.050 |
Why?
| Interleukin-6 | 1 | 2022 | 261 | 0.050 |
Why?
| Anti-Inflammatory Agents | 1 | 2022 | 163 | 0.050 |
Why?
| Biological Assay | 1 | 2021 | 45 | 0.050 |
Why?
| Taurine | 1 | 2020 | 18 | 0.040 |
Why?
| Acyltransferases | 1 | 2020 | 25 | 0.040 |
Why?
| Herb-Drug Interactions | 1 | 2020 | 31 | 0.040 |
Why?
| Toxicity Tests | 1 | 2020 | 54 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 93 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2020 | 85 | 0.040 |
Why?
| Cytochrome P-450 CYP1A2 | 1 | 2020 | 38 | 0.040 |
Why?
| Glutamine | 1 | 2020 | 175 | 0.040 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2020 | 77 | 0.040 |
Why?
| Hepatectomy | 1 | 2019 | 22 | 0.040 |
Why?
| Carbachol | 1 | 2019 | 27 | 0.040 |
Why?
| Respiratory Hypersensitivity | 1 | 2019 | 17 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 151 | 0.040 |
Why?
| Thinness | 1 | 2019 | 44 | 0.040 |
Why?
| Organ Culture Techniques | 1 | 2019 | 47 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 215 | 0.040 |
Why?
| Acylation | 1 | 2018 | 7 | 0.040 |
Why?
| Albuterol | 1 | 2019 | 57 | 0.040 |
Why?
| Software | 1 | 2020 | 276 | 0.040 |
Why?
| Galactosamine | 1 | 2016 | 4 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 313 | 0.030 |
Why?
| Microscopy, Fluorescence, Multiphoton | 1 | 2015 | 6 | 0.030 |
Why?
| Injections, Intraperitoneal | 1 | 2015 | 59 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2016 | 296 | 0.030 |
Why?
| Linear Models | 1 | 2016 | 279 | 0.030 |
Why?
| Apoptosis Inducing Factor | 1 | 2015 | 4 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2015 | 137 | 0.030 |
Why?
| Lipopolysaccharides | 1 | 2016 | 197 | 0.030 |
Why?
| Fatty Acids | 1 | 2015 | 144 | 0.030 |
Why?
| Asthma | 1 | 2019 | 284 | 0.030 |
Why?
| Blood Coagulation | 1 | 2015 | 60 | 0.030 |
Why?
| Bile Acids and Salts | 1 | 2015 | 78 | 0.030 |
Why?
| Anesthetics, Local | 1 | 2015 | 76 | 0.030 |
Why?
| Tyrosine | 1 | 2015 | 94 | 0.030 |
Why?
| NF-kappa B | 1 | 2016 | 315 | 0.030 |
Why?
| Poisoning | 1 | 2014 | 19 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 179 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 123 | 0.030 |
Why?
| Subcellular Fractions | 1 | 2014 | 33 | 0.030 |
Why?
| Disease Susceptibility | 1 | 2014 | 88 | 0.030 |
Why?
| Gene Expression Profiling | 1 | 2019 | 1025 | 0.030 |
Why?
| Oxypurinol | 1 | 2013 | 1 | 0.030 |
Why?
| Granulocytes | 1 | 2014 | 26 | 0.030 |
Why?
| Metallothionein | 1 | 2013 | 8 | 0.030 |
Why?
| Blotting, Western | 1 | 2015 | 578 | 0.030 |
Why?
| Xanthine Oxidase | 1 | 2013 | 15 | 0.030 |
Why?
| tert-Butylhydroperoxide | 1 | 2013 | 5 | 0.030 |
Why?
| Mitochondrial Diseases | 1 | 2014 | 41 | 0.030 |
Why?
| Mice, Inbred C3H | 1 | 2013 | 85 | 0.030 |
Why?
| Dimethyl Sulfoxide | 1 | 2013 | 13 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| Ketones | 1 | 2012 | 9 | 0.030 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2012 | 22 | 0.030 |
Why?
| Dipeptides | 1 | 2012 | 22 | 0.030 |
Why?
| 3-Hydroxybutyric Acid | 1 | 2012 | 2 | 0.030 |
Why?
| RNA, Messenger | 1 | 2016 | 1089 | 0.030 |
Why?
| Hepatomegaly | 1 | 2012 | 7 | 0.020 |
Why?
| Sulfates | 1 | 2012 | 24 | 0.020 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 91 | 0.020 |
Why?
| Glucuronides | 1 | 2012 | 45 | 0.020 |
Why?
| Oxidants | 1 | 2012 | 54 | 0.020 |
Why?
| Inflammasomes | 1 | 2012 | 62 | 0.020 |
Why?
| Lactic Acid | 1 | 2012 | 75 | 0.020 |
Why?
| Proteins | 1 | 2014 | 339 | 0.020 |
Why?
| Triglycerides | 1 | 2012 | 160 | 0.020 |
Why?
| Amiodarone | 1 | 2011 | 22 | 0.020 |
Why?
| Carrier Proteins | 1 | 2012 | 298 | 0.020 |
Why?
| Fatty Liver | 1 | 2012 | 130 | 0.020 |
Why?
| Lipid Peroxidation | 1 | 2011 | 96 | 0.020 |
Why?
| Cell Survival | 1 | 2012 | 589 | 0.020 |
Why?
| Immunity, Innate | 1 | 2011 | 105 | 0.020 |
Why?
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2008 | 1 | 0.020 |
Why?
| Chaperonins | 1 | 2008 | 3 | 0.020 |
Why?
| Protein Folding | 1 | 2008 | 48 | 0.020 |
Why?
| Protein Conformation | 1 | 2008 | 162 | 0.020 |
Why?
| Binding Sites | 1 | 2008 | 362 | 0.020 |
Why?
| Models, Molecular | 1 | 2008 | 334 | 0.020 |
Why?
| Child | 1 | 2020 | 6906 | 0.020 |
Why?
| United States | 1 | 2016 | 4955 | 0.020 |
Why?
|
|
Mcgill's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|